Asia Pacific Multi-cancer Early Detection Market (By Type: Liquid Biopsy, Gene Panel, LDT; By End-use: Hospitals, Diagnostic Laboratories) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The Asia Pacific multi-cancer early detection market size was estimated at around USD 184.98 million in 2023 and it is projected to hit around USD 567.89 million by 2033, growing at a CAGR of 11.87% from 2024 to 2033.

Key Pointers

• The gene panel, LDT, and others segment led the multi-cancer early detection market with the largest share of 100% in 2023. 
• The hospitals segment held the largest revenue share of 52% in 2023.

Asia Pacific Multi-cancer Early Detection Market Overview

The Asia Pacific region is witnessing a paradigm shift in cancer detection strategies, with a growing emphasis on multi-cancer early detection (MCED) approaches. As advancements in medical technology and research continue to unfold, the landscape of cancer diagnosis is evolving rapidly.

Asia Pacific Multi-cancer Early Detection Market Growth Factors

The growth of the Asia Pacific multi-cancer early detection market is propelled by an advancements in technology, particularly in genomic sequencing and liquid biopsy techniques, have revolutionized cancer diagnosis, enabling the detection of multiple cancer types at earlier stages. Secondly, the rising burden of cancer in the region underscores the urgent need for more effective screening methods to mitigate the impact of this disease. Additionally, shifting healthcare policies that prioritize preventive care and investment in early detection initiatives contribute to market expansion. These factors collectively drive the adoption of multi-cancer early detection solutions, offering significant growth opportunities for market players across the Asia Pacific region.

Report Scope of the Asia Pacific Multi-cancer Early Detection Market

Asia Pacific Multi-cancer Early Detection Market Trends:

• Rising Cancer Burden: There's a notable increase in the prevalence of cancer across the Asia Pacific region, driving the demand for more effective screening methods to detect malignancies at their earliest stages.
• Shifting Healthcare Policies: Governments and healthcare organizations are increasingly prioritizing preventive care and investing in early detection initiatives to address the growing burden of cancer and improve patient outcomes.
• Adoption of Personalized Medicine: There's a growing trend towards personalized medicine in cancer care, with MCED solutions being tailored to individual patient profiles and genetic predispositions, thereby enhancing diagnostic accuracy and treatment effectiveness.
• Integration of AI and Big Data Analytics: The integration of artificial intelligence (AI) and big data analytics into multi-cancer early detection processes is enabling healthcare providers to analyze vast amounts of patient data quickly and accurately, leading to more precise diagnoses and treatment decisions.
• Emphasis on Education and Awareness: There's an increasing focus on raising awareness among both healthcare professionals and the general public about the importance of early cancer detection and the availability of MCED screening programs, aiming to increase participation rates and improve overall outcomes.

Type Insights

The gene panel, LDT, and others segment led the multi-cancer early detection market with the largest share of 100% in 2023. The segment’s dominance is attributed to the rising commercialization of tests. For the simple reason that they are generated and utilized in the same facility, Lab-developed Tests (LDTs) are launched into the market without FDA approval or any other independent regulatory assessment.

For instance, in May 2023, Guardant Health launched Shield, an LDT blood test, for the detection of early signs of colorectal cancer in the adult population aged above 45 years. Moreover, in December 2021, GRAIL finished recruiting participants for PATHFINDER, a prospective, multisite interventional study with 6,600 participants, which was carried out in accordance with a U.S. Food and Drug Administration Investigational Device Exemption application to assess the use of Galleri in clinical practice.

The liquid biopsy segment is expected to showcase the fastest CAGR over the forecast period owing to the expected launch of promising products post-FDA approval, which are currently being made available as LDTs. Liquid biopsy technology is one of the most evolving technologies in diagnostics. An increasing number of players are receiving funding from investors for the development of new tests.

For instance, in July 2023, Delfi Diagnostics, Inc. received funding of USD 225 million for the development of a high-performance and accessible MCED test. The company is working on reducing the cost of the test to make it more accessible to the masses. Liquid biopsy technologies have made remarkable progress in recent years, with a large increase in clinical application uptake.

End-use Insights

The hospitals segment held the largest revenue share of 52% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. Hospitals are preferred for care due to the availability of various services under one roof. Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services within their settings.

For instance, in September 2023, Henry Ford Health was the first medical center to provide Grail’s Galleri MCED test in Michigan to increase cancer detection and improve public health. Moreover, in December 2023, Mercy Hospital in St. Louis announced that it will begin testing for cancer that is still in its development stage with Galleri test, which can be used to detect around 50 different cancers.

The diagnostic laboratories segment is expected to show a significant growth rate over the projected period owing to increased testing and availability of resources for performing tests. There has been an improved reliance of hospitals on diagnostic laboratories for evaluation and testing, which is likely to accelerate segment growth.

Moreover, regulatory authorities are undertaking initiatives to improve clinical laboratory diagnostic services to simplify the diagnosis process. For instance, in January 2021, WHO published the first Essential Diagnostics List, a catalog of tests required to diagnose common diseases. Some of the tests mentioned in this list are especially suitable for primary healthcare facilities where laboratory services are, at times, nonexistent or poorly resourced.

Asia Pacific Multi-cancer Early Detection Market Key Companies

• Grail, LLC (Illumina, Inc.)
• Exact Sciences Corporation
• AnchorDx
• Guardant Health
• Burning Rock Biotech Limited
• GENECAST
• Singlera Genomics Inc.
• Laboratory for Advanced Medicine, Inc.
• MiRXES Pte Ltd.

Asia Pacific Multi-cancer Early Detection Market Segmentation:

By Type 

• Liquid Biopsy
• Gene Panel, LDT & Others

By End-use 

• Hospitals
• Diagnostic Laboratories
• Others